A meta-analysis of gene expression data found that GLP-1 receptor and CREB1 are consistently upregulated in osteoarthritis cartilage, suggesting incretin-pathway modulation could be a new therapeutic angle for joint disease.
GLP1R +0.518GLP-1 receptor expression was significantly elevated in osteoarthritis cartilage across four independent datasets with zero heterogeneity.
What the researchers found
CREB1 and GLP1R were significantly upregulated in OA cartilage across multiple cohorts with zero heterogeneity (I² = 0%), while ADCY3 was downregulated, revealing a disrupted incretin-cAMP signaling axis.
Why it matters
Osteoarthritis currently has no disease-modifying treatments. Finding that GLP-1 receptor signaling is altered in OA cartilage opens the door to repurposing existing GLP-1 receptor agonist drugs — already widely used for diabetes and obesity — as potential joint-protective therapies.
The numbers in context
Meta-analysis of multiple transcriptomic datasets examining four genes (GLP1R, GIPR, ADCY3, CREB1) across osteoarthritis cohorts.
How the study worked
Integrative meta-analysis of four GEO transcriptomic datasets (N=83) using random-effects models, machine learning classifiers with leave-one-dataset-out validation, and functional enrichment analysis.
Who was studied
Osteoarthritis cartilage samples from public transcriptomic datasets
What this study cannot tell us
All data came from publicly available transcriptomic datasets with a combined sample size of only 83, limiting statistical power. The diagnostic classifier performance was modest (AUC 0.684). No functional experiments were performed to validate the proposed signaling axis, and the study cannot determine whether gene expression changes are causes or consequences of OA.
How to read the evidence
This is a meta-analysis of observational transcriptomic data. While the consistency across cohorts (I²=0%) strengthens the finding, the small combined sample size (N=83) and lack of functional validation keep this at a preliminary evidence level.
When this study was published
Published in 2025, this represents the current frontier of research connecting incretin signaling to joint disease.
The bigger picture
GLP-1 receptor agonists like semaglutide are reshaping metabolic medicine. Evidence that GLP-1R is overexpressed in osteoarthritis cartilage adds to a growing body of research suggesting these drugs may have anti-inflammatory and tissue-protective effects far beyond blood sugar control — potentially extending to joint health.
Questions still open
- Could existing GLP-1 receptor agonists slow cartilage degradation in osteoarthritis patients?
- Is CREB1 upregulation a compensatory protective response or a driver of OA pathology?
- Would intra-articular delivery of incretin-pathway modulators be more effective than systemic administration?
Common questions
Could GLP-1 drugs like semaglutide help with arthritis?
What is CREB1 and why does it matter for joints?
Read the original research
Meta-analysis of GLP1R, GIPR, ADCY3, and CREB1 expression in osteoarthritis identifies CREB1 as a potential biomarker and therapeutic target.
Journal of clinical orthopaedics and trauma, 71, 103256
Citation
Alizargar, Javad. (2025). Meta-analysis of GLP1R, GIPR, ADCY3, and CREB1 expression in osteoarthritis identifies CREB1 as a potential biomarker and therapeutic target.. Journal of clinical orthopaedics and trauma, 71, 103256. https://doi.org/10.1016/j.jcot.2025.103256